UroGen Pharma Q1 2023 JELMYTO revenue $17.2M (+27% YoY); net loss $30.2M

UroGen Pharma Ltd.

JELMYTO net product revenue $17.2M, up ~27% from $13.6M in Q1 2022.
Net loss $30.2M ($1.30 per share) vs $28.4M ($1.25 per share) in Q1 2022.
Cash and marketable securities $75.2M as of March 31, 2023.
Reiterated FY 2023 JELMYTO revenue guidance $76-86M; operating expenses $135-145M.
Topline data from ENVISION and ATLAS trials for UGN-102 expected summer 2023; NDA submission planned for 2024.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

UroGen Pharma Ltd. reported the first quarter ended March 31, 2023 results: revenue $17.2 million, net income $30.2 million. Guidance reaffirmed.

Period: the first quarter ended March 31, 2023
Revenue: $17.2 million
Net income: $30.2 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

99.1 UroGen Pharma Meets Revenue Goal, Reports First Quarter 2023 Financial Results and Recent Corporate Developments • Reported JELMYTO ® Q1 2023 net product revenues of $17.2 million, an increase of ~27% from Q1 2022 • Complete Response data from ENVISION pivotal trial and topline data readout from ATLAS trial on track for summer 2023 PRINCETON, N.J. May 11,

View on SEC.gov

Browse all earnings releases →

UroGen Pharma Ltd. filing history →

Source: SEC EDGAR

accession 0001193125-23-141462

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.